Last $10.81 USD
Change Today +0.16 / 1.50%
Volume 16.3K
PRTO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

proteon therapeutics inc (PRTO) Snapshot

Open
$10.76
Previous Close
$10.65
Day High
$10.81
Day Low
$10.68
52 Week High
01/9/15 - $12.65
52 Week Low
12/8/14 - $8.57
Market Cap
177.8M
Average Volume 10 Days
21.1K
EPS TTM
$-59.67
Shares Outstanding
16.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTEON THERAPEUTICS INC (PRTO)

Related News

No related news articles were found.

proteon therapeutics inc (PRTO) Related Businessweek News

No Related Businessweek News Found

proteon therapeutics inc (PRTO) Details

Proteon Therapeutics Inc develops pharmaceuticals to treat renal and vascular diseases. The company is developing PRT-201, a recombinant human elastase, which is in Phase III clinical trials for the treatment of radiocephalic arteriovenous fistula; and has completed a Phase I/II trial for the treatment of patients undergoing surgical placement of an arteriovenous graft. The company was founded in 2001 and is based in Waltham, Massachusetts.

11 Employees
Last Reported Date: 11/25/14
Founded in 2001

proteon therapeutics inc (PRTO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $440.9K
Vice President of Marketing & Business Develo...
Total Annual Compensation: $242.4K
Compensation as of Fiscal Year 2013.

proteon therapeutics inc (PRTO) Key Developments

Proteon Therapeutics Inc. Announces Publication of Nonclinical Data on PRT-201

Proteon Therapeutics Inc. announced publication of nonclinical data on PRT-201 (vonapanitase) in peripheral artery disease (PAD). This ex vivo study evaluated the effect of a single treatment of PRT-201, an investigational drug, on atherosclerotic human arteries. The positive results, published in the December issue of the Journal of Cardiovascular Pharmacology, support Proteon's clinical development program in PAD. Proteon's Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. PRT-201 has the potential to treat patients suffering from a number of renal or vascular diseases for which there currently are limited therapeutic options, including PAD. The results published in the Journal of Cardiovascular Pharmacology support Proteon's ongoing Phase 1 clinical study of PRT-201, which enrolled patients with symptomatic PAD of the superficial femoral or popliteal artery. Immediately following angioplasty, patients received PRT-201 delivered to the arterial wall via a catheter-based approach using the Mercator MedSystems Bullfrog® Micro-Infusion Device.

Proteon Therapeutics Inc Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:30 PM

Proteon Therapeutics Inc Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 04:30 PM. Venue: The Waldorf Astoria, New York, New York, United States.

Proteon Therapeutics Inc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 08:35 AM

Proteon Therapeutics Inc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 08:35 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTO:US $10.81 USD +0.16

PRTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTO.
View Industry Companies
 

Industry Analysis

PRTO

Industry Average

Valuation PRTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEON THERAPEUTICS INC, please visit www.proteontherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.